Catalyst
Slingshot members are tracking this event:
Gilead Begins Phase 3 Study of Eleclazine for Treatment of Long QT-3 Syndrome - Data Readout Expected H1 of 2017 - Terminated
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02300558?term=Eleclazine&rank=1
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Eleclazine, Gs-6615, Long Qt-3 Syndrom, Data Readout
